Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021

Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) announced a live conference call and audio webcast on August 12, 2021, at 4:30 p.m. ET to discuss its second-quarter financial results and provide a clinical update. The call can be accessed via phone or through the company's website. Atea focuses on developing oral therapeutics for severe viral infections, utilizing a proprietary nucleotide prodrug platform for treating viruses such as SARS-CoV-2, HCV, and RSV. For more information, visit Atea Pharmaceuticals.

Positive

• Atea Pharmaceuticals is developing oral therapeutics for severe viral infections, indicating potential growth in a crucial healthcare sector.
• The company's proprietary nucleotide prodrug platform positions it well for addressing unmet medical needs in antiviral treatment.

Negative

• None.

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, August 12, 2021 at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2021, and to provide a clinical and corporate update.

To access the live conference call, please dial (833) 301-1150 (domestic) or (914) 987-7391 (international) at least five minutes prior to the start time, and refer to conference ID 5795073. A live audio webcast of the call and accompanying slide presentation will be available in the Investors’ Events & Presentations section of the Company's website, www.ateapharma.com. An archived webcast will be available on the Atea website approximately two hours after the event.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapeutics to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com

FAQ

When will Atea Pharmaceuticals report its second-quarter financial results?

Atea Pharmaceuticals will report its second-quarter financial results on August 12, 2021, at 4:30 p.m. ET.

What is the focus of Atea Pharmaceuticals?

Atea Pharmaceuticals focuses on developing oral therapeutics to treat life-threatening viral diseases, including those caused by SARS-CoV-2 and HCV.

How can I access Atea Pharmaceuticals' conference call?

To access the conference call, dial (833) 301-1150 for domestic or (914) 987-7391 for international participants and refer to conference ID 5795073.